[1] Zhao H,Xu L,Yang Y,et al.Successful management of decitabine prior to full-dose idarubic in and cytarabine in the treatment of refractory/recurrent acute myeloid leukemia［J］.Acta Haematologica,2017，137(4):195-200.
[2]O'Donnell MR,Tallman MS,Abboud CN,et al.Acute myeloid leukemia,version 3.2017,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2017，15(7)：926-957.
[3] Stahl M,Lu BY,Kim TK,et al.Novel therapies for acute myeloid leukemia:Are we finally breaking the deadlock［J］? Target Oncol,2017，12(4):413-447.
[4] Dohner H,Estey E,Grimwade D,et al.Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel［J］.Blood,2017，129(4):424-447.
[5]WANG SF，ZHAO HY，HUANG J，et al．Progress in the treatment of elderlyacute myeloid leukemia［J］．Chinese Journal of Experimental Hematology，2017，25(4):1271-1274．［汪少飞，赵会英，黄静,等．老年急性髓系白血病治疗进展［J］．中国实验血液学杂志，2017，25(4):1271-1274．］
[6]Schroeder T,Rautenberg C,Haas R,et al.Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation［J］.Int J Hematol,2018,107(2):138-150.
[7]Khan N,Hantel A,Knoebel RW,et al.Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia［J］.Leuk Lymphoma,2017,58(9):1-7.
[8] Issa JP，Garcia-Manero G，Huang X，et al．Ｒesults of phase 2 randomized study of low-dose decitabine with or without valproicacidin patients with myelodysplastic syndrome and acute myelogenousleukemia［J］．Cancer，2015，121(4):556-561．
[9]Koistintn P,Raty R,Itala M,et al.Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia(AML):The nationwide AML-92 study by the Finnish Leukaemia Group ［J］.Eur J Haematol,2007(78):477-486.
[10]ZHANG ZN，SHEN T．Agent efficacy criteria in diagnosis of hematological disease［M］．3rd ed.Beijing:Science Press，2007:131-133，271．［张之南，沈悌．血液病诊断及疗效标准［M］．第3版.北京:科学技术出版社，2007:131-133，271．］
[11] CHEN JF，DU X，WENG JY，et al．Analysis of the efficacy and prognosticfactors of induction of remission chemotherapy in elderly patientswith acute myeloid leukemia［J］．Guangdong Medical Journal，2016，37(16):2437-2440．［陈吉藩，杜欣，翁建宇，等．老年急性髓系白血病的诱导缓解化疗疗效和预后因素分析［J］．广东医学，2016，37(16):2437-2440．］
[12] Gurion R，Vidal L，Gafter-Gvili A，et al.5-azacitidineprolongs overall survival in patients with myelodysplastic syndrome-a systematic review and meta-analysis［J］．Haematologica，2010，95(2):303-310．
[13] Huang J,Hong M,Zhu Y,et al.Decitabine in combination with G-CSF,low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia［J］.Leuk Lymphoma,2018，4(4):1-10.
[14]Halpern AB,Othus M,Huebner EM,et al.Mitoxantrone,etoposide,andcytarabine（MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms:A phase 1/2 study［J］.Leukemia，2017，31(12):2560-2567.
[15] Kurimoto M，Matsuoka H，Hanaoka N，et al．Pretreatment of leukemic cells with low-dose decitabine marked lyenhances the cytotoxicity of gemtuzumabozogamicin［J］．Leukemia，2013，27(1):233-235．
[16] Mayer J，Arthur C，Delaunay J，et al．Multivariate and subgroup analyses of a randomized，multinational，phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloidleukemia and poor-or intermediate-risk cytogenetics［J］．BMC Cancer，2014(14):69．
[17] Daver N,Kantarjian H,Ravandi F,et al.A phaseⅡ study of decitabine and gemtuzumabozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome［J］.Leukemia,2016,30(2):268-273.
[18]LU Xiaoyun,XU Ruiqin.Clinical effect analysis of decitabine combined with CAG regimen in the treatment of acute myeloid leukemia in the elderly ［J］.J Clin Hematol,2017,30（9):697-700.［陆小云，徐瑞琴．地西他滨联合CAG方案治疗老年急性髓系白血病的临床效果分析［J］．临床血液学杂志，2017，30(9):697-700．］
[19] YANG Yichun,SHI Lin,WANG Jianyu,et al.Therapeutic effect of decitabine regimen in the treatment of 26 patients with acute myeloid leukemia ［J］.J Clin Hematol,2018,31(5):50-52,55.［杨懿春，石林，王建渝，等．含地西他滨方案治疗老年急性髓系白血病26例疗效分析［J］．临床血液学杂志，2018,31（5）：50-52,55.］
[20] Song LX，Xu L，Li X，et al．Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia［J］．Ann Hematol，2012，91(12):1879-1886．
[21]YU Wenzheng.Comparison of the efficacy of economical HAG/CAG regimen in the treatment of elderly acute myeloid leukemia and high-risk myelodysplastic syndrome ［J］.Chin J Gerontol,2012,32（19):4313-4314.［于文征．经济型HAG/CAG方案治疗老年急性髓细胞白血病及高危骨髓增生异常综合征疗效比较［J］．中国老年学杂志，2012，32（19）：4313-4314．］
[22]WU Dijiong,YE Baodong,SHEN Jianping,et al.Clinical observation of low-dose HA/HAA regimen in the treatment of acute myeloid leukemia in the elderly ［J］.Chin J Hematol,2014,35（3):256-259.［吴迪炯，叶宝东，沈建平，等．小剂量HA/HAA方案诱导治疗老年急性髓系白血病临床观察［J］．中华血液学杂志，2014，35（3）：256-259．］
[23] Yamada K，Furusawa S，Saito K，et al．Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia:A pilot study［J］．Leukemia，1995，9(1):10-14．
[24] CHEN Guang,LU Yifeng,ZHU Lingling,et al.Clinical efficacy of decitabine combined with CAG regimen in the treatment of acute myeloid leukemia in the elderly［J］.Chinese Medical Science,2017，7(11):62-64.［陈光,陆屹峰,朱玲玲,等.地西他滨联合 CAG 方案治疗老年急性髓系白血病临床疗效观察［J］.中国医药科学,2017，7(11):62-64.］
[25] SHI Huiying,LIU Zhuogang,LI Jia,et al.Comparison of the efficacy of HAG and HA regimens in the treatment of acute myeloid leukemia M2 in the early stage of diagnosis［J］.Laboratory Medicine and Clinic,2017,14(3):406-408.［石卉莹，刘卓刚，李佳，等.HAG和HA方案治疗老年初诊急性髓系细胞白血病M2型疗效对比［J］.检验医学与临床,2017,14(3):406-408.］
[26] FENG Guangjia，LONG Zhiguo．Clinical comparison study of priming induction regimen of decitabine+CAG and HAG in the treatmentfor newly diagnosed acute myeloid leukemia in elderly patients［J］.Practical Geriatrics,2017,31(7):670-673.［冯广加,龙志国.地西他滨+CAG与HAG治疗老年初治急性髓性白血病的对比研究［J］.实用老年医学,2017,31(7):670-673.］
[27] Roberts DA，Steensma DP．Outlook and management of patients with myelodysplastic syndromes failed by hypomethylating agents［J］．Curr Hematol Malig Ｒep，2015，10(3):318-328．